Skip to main content

Table 1 Patient demographics between groups

From: Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women

Variable

CAP-B (n = 130)

CAP (n = 133)

P-value

Age at onset (years)

68.6 ± 8.43

69.1 ± 8.27

0.247*a

Site of primary tumour

  

0.806*b

 Caecum to transverse colon

58

60

 

 Splenic flexure to rectum

47

52

 

 Multiple sites

25

21

 

Duration of treatment (mos)

24.2 ± 18.14

24.7 ± 21.33

0.129*a

Performance Status(ECOG)

  

0.514*b

 0

76

83

 

 1

54

50

 

Number of metastatic sites

  

0.586*b

 1

57

62

 

  > 1

43

40

 

 unknown

30

31

 

Best response to induction treatment

  

0.612*b

 Stable disease

52

59

 

 Partial response

36

35

 

 Complete response

11

13

 

 No change

21

18

 

 Progression

10

8

 

Time from induction treatment to start of maintenance treatment

  

0.385*b

  ≤ 1 mos

102

110

 

  > 1 mos

28

23

 

Primary site

  

0.639*b

 Colon

52

57

 

 Rectum

78

76

 
  1. *No statistically significant values. aAnalysed using an Independent-Samples t-test; bAnalysed using the Mann-Whitney test. CAP-B capecitabine plus bevacizumab, CAP capecitabine, ECOG Eastern Collaborative Oncology Group